基本信息
文件名称：Tofacitinib-13C3-15N-Tasocitinib-sup-13-sup-C-sub-3-sub-sup-15-sup-N-生命科学试剂-MCE.pdf
文件大小：458.51 KB
总页数：1 页
更新时间：2025-05-21
总字数：约3.43千字
文档摘要

Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

Tofacitinib-13C3,15N

Cat.No.:HY-40354S1

Synonyms:Tasocitinib-13C,15N;CP-690550-13C,15N

33

分?式:C????C?H??N???NO

分?量:329.36

作?靶点:Isotope-LabeledCompounds;JAK;Apoptosis

作?通路:Others;Epigenetics;JAK/STATSignaling;ProteinTyrosine

Kinase/RTK;StemCell/Wnt;Apoptosis

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性Tofacitinib-13C3,15N(Tasocitinib-13C3,15N)是13C和15N标记的Tofacitinib.Tofacitinib是JAK3/2/1抑制

剂，IC50分别为1，20和112nM。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumSubst